Onconase is being evaluated in a Phase IIIb trial for the treatment of UMM.

Alfacell entered into a purchase and supply agreement with Scientific Protein Laboratories (SPL) for the commercial production of its anticancer drug. Onconase is currently in a Phase IIIb trial for unresectable malignant mesothelioma (UMM).

“SPL has been involved in the production of Onconase from the very first batches,” says Kuslima Shogen, CEO of Alfacell. “This agreement is another step forward for Alfacell as we plan for the commercialization of Onconase.”

Just three days ago, Alfacell licensed U.S. commercialization rights for Onconase to Strativa Pharmaceuticals. Alfacell could reap $225 million through this deal with Strativa.

Previous articleHelix BioMedix Inks Peptide Production and Supply Deal with Peptisyntha
Next articleDiscovery of Gene’s Duality in Cell Regulation Leads to Understanding of Its Role as Tumor Suppressor